AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes - PubMed (original) (raw)
Review
AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes
W W Winder et al. Am J Physiol. 1999 Jul.
Abstract
Adenosine 5'-monophosphate-activated protein kinase (AMPK) now appears to be a metabolic master switch, phosphorylating key target proteins that control flux through metabolic pathways of hepatic ketogenesis, cholesterol synthesis, lipogenesis, and triglyceride synthesis, adipocyte lipolysis, and skeletal muscle fatty acid oxidation. Recent evidence also implicates AMPK as being responsible for mediating the stimulation of glucose uptake induced by muscle contraction. In addition, the secretion of insulin by insulin secreting (INS-1) cells in culture is modulated by AMPK activation. The net effect of AMPK activation is stimulation of hepatic fatty acid oxidation and ketogenesis, inhibition of cholesterol synthesis, lipogenesis, and triglyceride synthesis, inhibition of adipocyte lipolysis and lipogenesis, stimulation of skeletal muscle fatty acid oxidation and muscle glucose uptake, and modulation of insulin secretion by pancreatic beta-cells. In skeletal muscle, AMPK is activated by contraction. Type 2 diabetes mellitus is likely to be a disease of numerous etiologies. However, defects or disuse (due to a sedentary lifestyle) of the AMPK signaling system would be predicted to result in many of the metabolic perturbations observed in Type 2 diabetes mellitus. Increased recruitment of the AMPK signaling system, either by exercise or pharmaceutical activators, may be effective in correcting insulin resistance in patients with forms of impaired glucose tolerance and Type 2 diabetes resulting from defects in the insulin signaling cascade.
Similar articles
- Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders.
Viollet B, Mounier R, Leclerc J, Yazigi A, Foretz M, Andreelli F. Viollet B, et al. Diabetes Metab. 2007 Dec;33(6):395-402. doi: 10.1016/j.diabet.2007.10.004. Epub 2007 Nov 7. Diabetes Metab. 2007. PMID: 17997341 Review. - Role of AMP--activated protein kinase in the control of glucose homeostasis.
Barnes BR, Zierath JR. Barnes BR, et al. Curr Mol Med. 2005 May;5(3):341-8. doi: 10.2174/1566524053766103. Curr Mol Med. 2005. PMID: 15892653 Review. - AMP-activated protein kinase: Role in metabolism and therapeutic implications.
Schimmack G, Defronzo RA, Musi N. Schimmack G, et al. Diabetes Obes Metab. 2006 Nov;8(6):591-602. doi: 10.1111/j.1463-1326.2005.00561.x. Diabetes Obes Metab. 2006. PMID: 17026483 Review. - AMP-activated protein kinase regulation and action in skeletal muscle during exercise.
Musi N, Yu H, Goodyear LJ. Musi N, et al. Biochem Soc Trans. 2003 Feb;31(Pt 1):191-5. doi: 10.1042/bst0310191. Biochem Soc Trans. 2003. PMID: 12546683 Review. - Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle.
Lee WJ, Song KH, Koh EH, Won JC, Kim HS, Park HS, Kim MS, Kim SW, Lee KU, Park JY. Lee WJ, et al. Biochem Biophys Res Commun. 2005 Jul 8;332(3):885-91. doi: 10.1016/j.bbrc.2005.05.035. Biochem Biophys Res Commun. 2005. PMID: 15913551
Cited by
- Upregulation of the AMPK-FOXO1-PDK4 pathway is a primary mechanism of pyruvate dehydrogenase activity reduction in tafazzin-deficient cells.
Liang Z, Ralph-Epps T, Schmidtke MW, Lazcano P, Denis SW, Balážová M, Teixeira da Rosa N Jr, Chakkour M, Hazime S, Ren M, Schlame M, Houtkooper RH, Greenberg ML. Liang Z, et al. Sci Rep. 2024 May 20;14(1):11497. doi: 10.1038/s41598-024-62262-1. Sci Rep. 2024. PMID: 38769106 Free PMC article. - l-Ornithine-l-Aspartate (LOLA) Normalizes Metabolic Parameters in Models of Steatosis, Insulin Resistance and Metabolic Syndrome.
Canbay A, Götze O, Kucukoglu O, Weinert S, Croner RS, Baars T, Özçürümez MK, Gieseler RK. Canbay A, et al. Pharmaceutics. 2024 Apr 7;16(4):506. doi: 10.3390/pharmaceutics16040506. Pharmaceutics. 2024. PMID: 38675168 Free PMC article. - Crosstalk between lipid metabolism and EMT: emerging mechanisms and cancer therapy.
Din ZU, Cui B, Wang C, Zhang X, Mehmood A, Peng F, Liu Q. Din ZU, et al. Mol Cell Biochem. 2024 Apr 15. doi: 10.1007/s11010-024-04995-1. Online ahead of print. Mol Cell Biochem. 2024. PMID: 38622439 Review. - Advances and Challenges in Modeling Cannabidiol Pharmacokinetics and Hepatotoxicity.
Beers JL, Zhou Z, Jackson KD. Beers JL, et al. Drug Metab Dispos. 2024 May 16;52(6):508-515. doi: 10.1124/dmd.123.001435. Drug Metab Dispos. 2024. PMID: 38286636 Review. - CTRP13 Mitigates Endothelial Cell Ferroptosis via the AMPK/KLF4 Pathway: Implications for Atherosclerosis Protection.
Du J, Wu J, Zhang Y, Liu Q, Luo X, Huang X, Wang X, Yang F, Hou J. Du J, et al. Med Sci Monit. 2024 Jan 26;30:e942733. doi: 10.12659/MSM.942733. Med Sci Monit. 2024. PMID: 38273650 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical